
PGY-4 Psychiatry 📚 Voz en 🎧 @lamaximapodcast por #Spotify 👇🏻 MANAGER @SolTaylorRdl
República Dominicana
Joined November 2009
- Tweets34.9K
- Following909
- Followers1.5K
- Likes5.2K
Pinned Tweet
ANATOMÍA DE HENRY wattpad.com/202672180 Médicos en proceso @MaximoCorporan La ética médica no siempre se cumple #Wattpad #Medicina
Desde las 11 de la mañana tratando de resolver un problema con una transacción en el @BanreservasRD y son las 7 de la noche y como 15 reportes, y todavía no resuelven.
Esos del servicio al cliente, solo saben hablar mal.
1
20
Acabo de renunciar a hacer las recetas de comida que veo en las redes, siempre termino haciendo un desastre.
17
No se dejen llevar de las apariencias en redes sociales, hay personas que parecen tener una gran vida, y eso en muchos caso, resulta ser una falacia.
13
Máximo Corporán, M.D. retweeted
Descubrimiento y aprobación por @FDA de los diferentes #Antidepresivos
Hoy tocó clase de #Psicofarmacología en @TecSaludMX para Residentes de 2do año de #Psiquiatría
El trastorno depresivo mayor necesita acompañamiento psicoterapéutico y tratamiento psicofarmacológico. No dejes de buscar ayuda, nadie mejora en el aislamiento.
23
Máximo Corporán, M.D. retweeted
Catatonia after stopping clozapine isn't just a coincidence to note — and if a patient is being switched to a drug that works the opposite way on the cholinergic system, it may make things worse before they get better. A "Rounds in the General Hospital" review in PCC lays out the mechanism: clozapine's chronic muscarinic effects can leave receptors upregulated, so abrupt withdrawal may trigger a rebound cholinergic surge — a known but underappreciated trigger for catatonia.
Takeaway: when catatonia follows clozapine withdrawal, restarting clozapine — not adding more antipsychotics — is the treatment of choice. Reserve other agents for cases refractory to lorazepam, clozapine restart, and ECT, and consider ECT early if malignant features (autonomic instability, fever, rigidity) emerge.
Read the full article here -----> psychiatrist.com/pcc/combini…
#Psychiatry #ClinicalPsychiatry #Clozapine #Catatonia #Schizophrenia #MentalHealth #PCC #Psychopharmacology #ClinicalReasoning
Máximo Corporán, M.D. retweeted
What’s changing in the way we understand and treat major depressive disorder? Find out August 22 at NEI Saturday Morning Live. Join Dr. Thomas Schwartz for a closer look at the evolving science of MDD, rapid-acting therapies, emerging treatment approaches, and strategies for improving patient outcomes. See what’s on the agenda and register for free: nei.global/26sml-august22
Máximo Corporán, M.D. retweeted
The U.S. Food and Drug Administration has approved oveporexton, an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 in adults. Read more nei.global/21200
Máximo Corporán, M.D. retweeted
Akathisia is a treatable medication side effect that causes an intense feeling of inner restlessness and a strong urge to keep moving. 🧠💊 It can occur with certain psychiatric medications and is often mistaken for anxiety or agitation.
Learn more 👉 youtube.com/watch?v=2h7RfHCI…
Máximo Corporán, M.D. retweeted
The U.S. Food and Drug Administration has approved centanafadine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in in adults and pediatric patients aged 6 years and older weighing at least 20kg. Centanafadine is a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI). Read more nei.global/21195
Máximo Corporán, M.D. retweeted
Centanafadine is likely to be approved by the FDA today for ADHD - a first in class NDSRI?
It is an reuptake inhibitor of the main monoamines: serotonin, dopamine, and norepinephrine
It differs from most currently available re-uptake inhibitors, which primarily target:
• serotonin (SSRIs)
• serotonin and norepinephrine (SNRIs)
• norepinephrine and dopamine (NDRIs/bupropion)
There is actually already another NDSRI, but folks don't want to mention it - cocaine. The kinetics make it pretty different though.
As always appropriate caution and skepticism is adequate with new psychotropics. ADHD is still a debated concept. Non-stimulant are much less used than stimulants for ADHD.
Ref for binding affinity- DOI: 10.1002/syn.21538










